相关实验视频
Updated: Jul 18, 2025

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.9K
使用杜洛特格拉维尔后的中枢神经系统疾病:临床前和临床研究的证据
Alicja Jakimiuk1, Agnieszka Piechal1, Alicja Wiercińska-Drapało2
1Department of Clinical and Experimental Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland.
Pharmacological reports : PR
|August 22, 2023
概括
长期使用多卢特格拉维尔可能会造成中枢神经系统 (CNS) 疾病的风险. 进一步的药物监测对于了解多洛特格拉维尔至关重要.
科学领域:
- 药理学和神经科学 药理学和神经科学
- 药物安全和药物监督 药物安全和药物监督
背景情况:
- 多卢特格拉维尔是一种用于治疗艾滋病毒的抗逆转录病毒药物.
- 人们担心其长期使用可能会对中枢神经系统 (CNS) 产生不良影响.
研究的目的:
- 评估与多卢特格拉维尔相关的中枢神经系统疾病的风险.
- 审查药物的药理动力学特征,特别是血脑屏障的透.
- 评估关于中枢神经系统不良事件和药物停药率的临床数据.
主要方法:
- 临床前和临床研究的系统审查.
- 对药物动力学数据的分析,包括血脑屏障的透.
- 检查临床试验中枢神经系统不良影响和停止治疗的数据.
主要成果:
- 现有数据表明,在长时间使用多卢特格拉维尔时,中枢神经系统疾病的潜在风险存在.
- 多卢特格拉维尔能够穿透血脑屏障是一个关键考虑因素.
- 总结了影响中枢神经系统疾病发生的因素.
结论:
- 长期使用杜洛特格拉维尔需要仔细监测中枢神经系统相关的不良事件.
- 药监管在描述新注册药物的安全性方面发挥着至关重要的作用,比如杜洛特格拉维尔.
- 需要继续进行研究,才能充分阐明杜洛特格拉维尔对中枢神经系统的安全性.
更多相关视频
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Disorders of the Nervous Tissue
1.4K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.4K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
CNS Depressants: Alcohol and Nicotine
243
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
243
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
344
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
344

